Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib plus radiotherapy to prevent radiation pneumonitis in lung cancer
ChiCTR2500112642Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of nintedanib in non-small cell lung cancer (NSCLC) and radiation pneumonitis (RP) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Incidence of grade ≥2 radiation pneumonitis. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)radiation pneumonitis (RP)
Beyond the preview
Go deeper on ChiCTR2500112642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112642.